These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34626573)

  • 1. Associations and Outcomes of Patients with Submacular Hemorrhage Secondary to Age-related Macular Degeneration in the IVAN Trial.
    Mehta A; Steel DH; Muldrew A; Peto T; Reeves BC; Evans R; Chakravarthy U;
    Am J Ophthalmol; 2022 Apr; 236():89-98. PubMed ID: 34626573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents, and Age-Related Macular Degeneration Study: A Randomized Controlled Trial for Submacular Hemorrhage Secondary to Age-Related Macular Degeneration.
    Gabrielle PH; Delyfer MN; Glacet-Bernard A; Conart JB; Uzzan J; Kodjikian L; Arndt C; Tadayoni R; Soudry-Faure A; Creuzot Garcher CP
    Ophthalmology; 2023 Sep; 130(9):947-957. PubMed ID: 37088447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Shah N; Maguire MG; Martin DF; Shaffer J; Ying GS; Grunwald JE; Toth CA; Jaffe GJ; Daniel E;
    Ophthalmology; 2016 Apr; 123(4):858-64. PubMed ID: 26778329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential tissue plasminogen activator, pneumatic displacement, and anti-VEGF treatment for submacular hemorrhage.
    Bardak H; Bardak Y; Erçalık Y; Erdem B; Arslan G; Timlioglu S
    Eur J Ophthalmol; 2018 May; 28(3):306-310. PubMed ID: 29148027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Displacement of Submacular Hemorrhage Using Subretinal Cocktail Injection versus Pneumatic Displacement: A Real-World Comparative Study.
    Szeto SKH; Tsang CW; Mohamed S; Lee GKY; Lok JKH; Hui VWK; Tsang KK; Chen LJ; Brelen M; Lai TYY
    Ophthalmologica; 2024; 247(2):118-132. PubMed ID: 38408445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
    Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J;
    Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
    Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related Macular Degeneration Treated with Anti-vascular Endothelial Growth Factor.
    Kim KH; Kim JH; Chang YS; Lee TG; Kim JW; Lew YJ
    Korean J Ophthalmol; 2015 Oct; 29(5):315-24. PubMed ID: 26457037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, risk factors and outcomes of submacular haemorrhage with loss of vision in neovascular age-related macular degeneration in daily clinical practice: data from the FRB! registry.
    Gabrielle PH; Maitrias S; Nguyen V; Arnold JJ; Squirrell D; Arnould L; Sanchez-Monroy J; Viola F; O'Toole L; Barthelmes D; Creuzot-Garcher C; Gillies M;
    Acta Ophthalmol; 2022 Dec; 100(8):e1569-e1578. PubMed ID: 35322568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration.
    Kim HS; Cho HJ; Yoo SG; Kim JH; Han JI; Lee TG; Kim JW
    Eye (Lond); 2015 Sep; 29(9):1141-51. PubMed ID: 26272443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration.
    Jain S; Kishore K; Sharma YR
    Indian J Ophthalmol; 2013 Sep; 61(9):490-6. PubMed ID: 24104707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Timing of Large Submacular Hemorrhage Secondary to Age-Related Macular Degeneration Relative to Anti-VEGF Therapy.
    Matsunaga DR; Su D; Sioufi K; Obeid A; Wibbelsman T; Ho AC; Regillo CD
    Ophthalmol Retina; 2021 Apr; 5(4):342-347. PubMed ID: 32763426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.
    Ying GS; Huang J; Maguire MG; Jaffe GJ; Grunwald JE; Toth C; Daniel E; Klein M; Pieramici D; Wells J; Martin DF;
    Ophthalmology; 2013 Jan; 120(1):122-9. PubMed ID: 23047002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitrectomy, subretinal Tissue plasminogen activator and Intravitreal Gas for submacular haemorrhage secondary to Exudative Age-Related macular degeneration (TIGER): study protocol for a phase 3, pan-European, two-group, non-commercial, active-control, observer-masked, superiority, randomised controlled surgical trial.
    Jackson TL; Bunce C; Desai R; Hillenkamp J; Lee CN; Lois N; Peto T; Reeves BC; Steel DH; Edwards RT; van Meurs JC; Wafa H; Wang Y
    Trials; 2022 Jan; 23(1):99. PubMed ID: 35101110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration.
    Karagiannis D; Chatziralli I; Kaprinis K; Georgalas I; Parikakis E; Mitropoulos P
    Clin Interv Aging; 2017; 12():1829-1833. PubMed ID: 29138543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Efficacy of Intravitreal Aflibercept in Submacular Hemorrhage Secondary to Wet Age-related Macular Degeneration.
    Shin KH; Lee TG; Kim JH; Kim JW; Kim CG; Lee DW; Han JI; Lew YJ; Cho HJ
    Korean J Ophthalmol; 2016 Oct; 30(5):369-376. PubMed ID: 27729757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.
    Treumer F; Wienand S; Purtskhvanidze K; Roider J; Hillenkamp J
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1115-1123. PubMed ID: 28280989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.